

# FRONTIERS IN CLINICAL TRIALS AND DRUG INTERACTIONS

**ISSN: ( 3065- 3975 )**



<https://multisciajournals.com/journals/index.php/fctdi>

editor.fctdi@gmail.com

# MiR-590-5P Inhibits HepG2 Cell Growth by Inhibiting the Wnt Pathway and Reducing S100A10 Expression

C Dichev, D Dicheva

Department of Clinical Trials and Drug Interactions

## Article Info

Received: 10-02-2025    Revised: 10-03-2025    Accepted: 20-03-2025    Published: 05-04-2025

---

**Abstract:** One of the most prevalent and deadly tumors in the world, particularly in underdeveloped nations, is hepatocellular carcinoma. In the current investigation, we discovered that six hepatocellular carcinoma cell lines had up-regulated S100A10 expression and down-regulated miR-590-5P expression. According to the reporter gene test, luciferase generated by a vector containing the 3' untranslated region of S100A10 mRNA was much less active when miR-590-5P was overexpressed. S100A10 expression was reduced by lentiviral infection-induced ectopic miR-590-5P overexpression. HepG2 cells that were infected with Lv-miR-590-5P experienced cell growth inhibition and cell cycle G1 arrest. Furthermore, the expression of miR-590-5P enhanced the phosphorylation of  $\beta$ -catenin and the production of Caspase 3, while suppressing the expression of Wnt5a, cMyc, and cyclin D1. These effects may be part of the mechanism by which miR-590-5P inhibits cell growth. When combined, our findings imply that hepatocellular carcinoma is associated with down-regulation of miR-590-5P and that restoring miR-590-5P might inhibit the proliferation of cancer cells, indicating that miR-590-5P may be a viable target molecule for hepatocellular carcinoma treatment.

**Keywords:** miR-590-5P; S100A10; hepatocellular carcinoma; Wnt pathway; lentiviral system; reporter gene

## 1. Introduction

One of the most prevalent malignancies in the world, hepatocellular carcinoma (HCC) is distinguished by its high prevalence, challenging prognosis, and high death rate. It accounts for 53% of all HCC-related fatalities worldwide, making it the second leading cause of cancer mortality in China [1]. Patients, their families, and society as a whole bear a heavy price as a consequence of the rising incidence and death rates. HCC is a complicated process that involves many different processes and circumstances, and the mechanisms behind its development have not yet been fully understood. To establish a theoretical foundation for diagnosis and therapy, it is critical to identify the genes regulating this process and comprehend the molecular genetics of HCC.

S100A10, commonly referred to as Annexin II light chain or p11, is a member of the low-molecular-weight EF-hand calcium-binding protein family, the S100 protein family, which is highly conserved. Its ability to bind calcium is eliminated by mutations in both of its EF-hands [2]. S100A10 often coexists in cells in the annexin A2 heterotetramer (AII<sub>t</sub>) with its natural ligand, annexin A2 (p36) [3–7]. The membrane localization of the AII<sub>t</sub> complex is mediated by the annexin A2 subunit. It has been shown that S100A10's interactions with a range of receptors (such as 5-HTR1B and 5-HTR4) and channel proteins (such as TASK-1, TRPV5, and TRPV6) influence their functional expression and cell surface presentation [8–12]. By interacting with plasminogen activators via its C-terminal lysine residues, S100A10 may also bind to plasminogen and cause plasminogen activation, which facilitates the conversion of plasminogen to plasmin [13]. Additional genetic research has shown that S100A10 is

essential for attracting macrophages to the tumor site, a process that may be facilitated by plasmin production triggered by S100A10 [14]. Our analysis of S100A10 expression in clinical samples from hepatocellular carcinoma and paraneoplastic tissues revealed that the cancer tissues had higher S100A10 levels. Therefore, further research is needed to determine its function in hepatocellular carcinoma as well as the regulation mechanism.

that miRNAs mediate several disease-related processes, including carcinogenesis. Recent studies have shown that known oncogenic miRNAs are up regulated in the liver of rats exposed to tamoxifen for 24 weeks [24]. Previously, Meng F *et al.* demonstrated that abnormal expression of miR-21 contributes to HCC growth and spreads through PTEN-dependent pathways [25]. In the present study, we identified another miRNA, miR-590-5P, which is involved in the growth and cell cycle regulation of hepatocellular carcinoma cells and explored implicated mechanisms through molecular and cellular techniques.

## 2. Results and Discussion

### 2.1. MiR-590-5P Is Down-Regulated and S100A10 Is Enhanced in Liver Cancer Cell Lines


Several human hepatocarcinoma cell lines and a normal liver cell line were examined for the presence of miR-590-5P and S100A10, respectively, using real-time PCR and western blotting. When compared to L-02 cells, all human hepatocarcinoma cell lines showed considerably lower expression of miR-590-5P ( $p < 0.01$ , Figure 1B). On the other hand, compared to L-02 cells, the S100A10 protein amounts in hepatocarcinoma cell lines were greater than those in normal liver cells (Figure 1C). The findings that S100A10 was highly expressed in hepatocarcinoma cells and miR-590-5P expression was down-regulated in human hepatocarcinoma cells, along with the bioinformatic analysis of the miR-590-5P and 3'-UTR of S100A10 sequences (Figure 1A), imply that there might be a negative correlation between the two. Therefore, we further examined the regulatory function of miR-590-5P in the production of S100A10 using the luciferase reporter system.

**Figure 1.** Bioinformatic analysis on the sequences of miR-590-5P and 3'-UTR of S100A10 and expression levels of miR-590-5P and S100A10 in human hepatocarcinoma cell lines and a normal liver cell line. (A) Alignment between miR-590-5p and S100A10 from microRNA.org (Targets and Expression); (B) Total RNA was extracted from the cells, and reversely transcribed and analyzed by quantitative PCR, and the expression level of miR-590-5P was normalized with internal control U6. The results are given as mean  $\pm$  SD of three independent experiments; (C) Cell lysates of the indicated cells were prepared, and S100A10 levels were determined by specific primary antibody against S100A10 followed by HRP-linked secondary antibody. The bands were visualized by enhanced a chemiluminescence detection system. One representative of three independent experiments is shown.

A

hsa-miR-590-5p/S100A10 Alignment	
3' gacgugaaaaaacUUUUUCGAg 5' hsa-miR-590-5p	mirSVR score: -1.2018 PhastCons score: 0.7698
164:5' aaguuaaaauaccaGAUAAGCUu 3' S100A10	


Figure 1. Cont.




## 2.2. MiR-590-5P Inhibits S100A10 Expression by Interacting with 3'UTR of S100A10 mRNA

In order to confirm whether miR-590-5P inhibits the expression of S100A10 via the 3'UTR of S100A10 mRNA, we cloned a 568-bp genomic segment into a pcDNA-copGFP vector to construct a pmiR-590-5P vector which was designed to express exogenous miR-590-5P. The expression miR-590-5P in 293 cells transfected with pmiR-590-5P significantly reduced the activity of firefly luciferase expressed by pGL-WT, which contains a wild type 3'UTR of S100A10 mRNA ( $p < 0.01$ , Figure 2). In addition, the mutation of the binding site abolished the inhibitory effect of miR-590-5P on the expression of the luciferase reporter ( $p > 0.05$ , Figure 2). Moreover, we used pmiR-590-5P to produce a lentivirus, Lv-miR-590-5p, to infect HepG2 cells. Fluorescence microscopic results showed that infection efficiency of Lv-miR-590-5p was over 90% (data not shown), real time PCR showed the lentiviral system effectively expressed miR-590-5p in HepG2 cells and western results showed miR-590-5P expression suppressed S100A10 expression significantly (Figure 3).

**Figure 2.** The 3'UTR of S100A10 enables miR-590-5P regulation. 293 cells were transfected with pmiR-590-5P construct with or without pGL-WT or pGL-MT. The histogram indicates relative firefly luciferase activities in the different transfected groups. Error bars represent standard deviation and were obtained from three independent experiments \*\*,  $t$ -test significant at  $p < 0.01$ .




**Figure 3.** S100A10 is down-regulated by infection of Lv-miR-590-5P. (A) HepG2 cells were infected with Lv-control or Lv-miR-590-5P. After 96 h, the cells were collected and total RNA was extracted and subjected to quantitative PCR. U6 was used as an internal standard; (B) HepG2 cells were infected with Lv-control or Lv-miR-590-5P, and after 96 hours, the cells were collected and total protein was extracted and subjected to western blotting. For western blotting, cell lysates were separated on a 14% (S100A10) or 13% (beta-actin) SDS polyacrylamide gel, and the blots were detected with a specific anti-S100A10 antibody, with beta-actin as an internal standard \*\*, *t*-test significant at  $p < 0.01$ . Data were confirmed in triplicate experiments.



### 2.3. The Over-Expression of miR-590-5P Inhibits Cellular Proliferation and Causes Cell Cycle Arrest in HepG2


HEPG2 cells infected with Lv-miR-590-5P or Lv-control were subjected to proliferation assay. The results shown in Figure 4 suggest that exogenous expression of miR-590-5P inhibited the proliferation of HepG2 cells. After 24 h or 48 h incubation, HepG2 infected with Lv-miR-590-5P showed no remarkable morphological change compared to the control, and there was no difference in cell numbers between the two groups ( $p > 0.05$ ) (Figure 4). However, the infection significantly inhibited the growth of HepG2 cells after 72 h, compared to the control group ( $p > 0.01$ ) (Figure 4). The results suggested that miR-590-5P overexpression induces growth inhibition of HepG2 cells in a time-dependent manner.

**Figure 4.** Effect of Lv-miR-590-5P on cell growth of HepG2 cells. HepG2 cells were infected by Lv-miR-590-5P or Lv-Control. The infected cells were reseeded to 96-wells plates. After incubation for indicated hours, the number of cells were detected by CCK-8 assay. The values represent the means  $\pm$  SD ( $n = 3$ ).



To investigate whether the inhibition of miR-590-5P on cell proliferation of HepG2 was mediated by cell cycle alteration, cell cycle distribution was analyzed. Histograms of flow cytometric data are shown in Figure 5. The results show that in comparison with the control group, miR-590-5P expression significantly increased cell population at the G1 phase (Figure 5), from  $46.92\% \pm 4.17\%$  to  $74.09\% \pm 6.09\%$  ( $p > 0.01$ ) (Figure 5D), indicating that overexpression of miR-590-5P causes a cell cycle G1 arrest in HepG2 cells.


**Figure 5.** Effect of miR-590-5P on cell cycle in HepG2 cell line. (A), (B) and (C) Cell cycle analysis produced by flow cytometry in HepG2 cells which were infected with or without Lv-Control or Lv-miR-590-5P; (D) Cell cycle distribution in percentages of the different groups. Data were obtained by flow cytometry and presented as mean ( $n = 3$ ).



#### 2.4. The Over-Expression of miR-590-5P Affects Wnt Pathway Signaling in HepG2 Cells

Since Wnt signaling pathway is an important pathway involved in primary liver cancer, we then detected several proteins and downstream target proteins in Wnt signaling pathway by western blotting. Results showed that lentiviral-mediated over-expression of miR-590-5P reduced the expression of Wnt5a and increased the phosphorylation of  $\beta$ -catenin (Figure 6). A protooncogene downstream of the Wnt signaling pathway, cMyc, was decreased by miR-590-5P over-expression. A similar result was obtained for cyclin D1, an important regulator for cell cycle progression. Conversely, Caspase 3 was increased in HepG2 by the over-expression of miR-590-5P.

**Figure 6.** Effects of miR-590-5P on the Wnt pathway and downstream proteins. HepG2 cells were infected with or without Lv-Control or Lv-miR-590-5P. Ninety six hours later, expression of Wnt5a, cMyc, cyclin D1, Caspase 3 and phosphorylation levels of  $\beta$ -catenin were determined by western blotting, using  $\beta$ -actin as a loading control.



Since miRNAs are involved in many diverse biological processes and pathological processes, they have become one of the main focuses in basic research and the research and development of applications [26]. By regulating genes through partially complementary sequences, miRNAs can influence extensively target genes. Recently, an increasing number of miRNAs were identified as playing roles in the carcinogenic process as oncogenes or as tumour suppressors, such as miR-335, miR-206, and miR-126 in breast cancer metastasis, miR-126, miR-143, and miR-145 in cervical cancer, and miRNA-451 in non-small cell lung cancer [27–29]. A previous study showed that miR-590-5P can inhibit the metastasis of breast cancer [30]. In addition, it was found that miR-590-5P is down-regulated in cervical cancer samples [31]. All the above-mentioned evidence indicates that miR-590-5P may act as a potential tumor suppressor gene. Among all the studies on hepatocellular carcinoma, we have demonstrated for the first time that interaction between S100A10 and miR-590-5P is involved in hepatocellular carcinoma.

Firstly, it was found that the expression of miR-590-5P was down-regulated in a number of hepatocellular carcinoma cell lines. The down-regulation of miR-590-5P may result in the dysregulation of its target genes. Here, the luciferase reporter gene assay revealed that S100A10 is a target gene of miR-590-5P, and the mutation in the binding site at 3'-UTR of S100A10 mRNA eliminates the regulatory effect of miR-590-5P.

Secondly, a lentiviral vector was used to express miR-590-5P in HepG2 cells, since the lentiviral system has several significant advantages in comparison with other viral or non-viral gene delivery system, including extensive target cells, high-efficiency infection of dividing and non-dividing cells, the ability to contain a large exogenous sequence for tissue-specific expression, persistent expression by gene integration into genomic DNA and low immunogenicity and toxic response [32–35]. In this study, the lentivirus was used to evaluate the effects of miR-590-5P restoration on cell growth and cell

cycle distribution. It was demonstrated that the lentiviral-mediated miR-590-5P expression efficiently reduced S100A10 protein and inhibited cell growth in HepG2 cells. Next, we also found that miR-590-5P restoration caused G1 phase arrest in HepG2 cells.

The Wnt gene family, of which the first member was identified as an oncogene involved in mouse breast cancers in 1982, plays a crucial role in the normal growth and development of mouse embryo [36]. Moreover, abnormal change in the Wnt signaling pathway, mediated by dysregulation or mutation of any component in the pathway, including  $\beta$ -catenin, adenomatous polyposis coli (APC) protein and glycogen synthase kinase 3 $\beta$  (GSK-3 $\beta$ ), is found in a variety of cancers, including esophageal cancer, colorectal cancer, melanoma, and primary liver cancer [37–39]. Therefore, we detected the effects of miR-590-5P on the Wnt pathway and several down-stream proteins. The results showed that miR-590-5P expression decreased the expression of Wnt5a and increased the phosphorylation level of  $\beta$ -catenin, which can induce its degradation by the ubiquitin-proteasome system [40]. An oncogene, c-myc, was reduced as well, contributing to the inhibited proliferative activity of HepG2. Cyclin D1 was decreased by miR-590-5P. As an important regulator of G1 to S-phase transition, the decrease of cycling D1 may mediate G1 arrest of HepG2 cells. In addition, Caspase 3 was increased by over-expression of miR-590-5P, indicating that miR-590-5P may also enhance the apoptosis under the experimental conditions. All these changes may be responsible for the inhibitory effect of miR-590-5P on the growth of HepG2, though further studies are required to confirm the mechanisms.

### **3. Experimental Section**

#### *3.1. Cell Culture*

L-02, QGY7701, HepG2, SMMC-7721, BEL-7402, Li-7, SK-HEP-1 and 293 cells were purchased from Cell Resource Center, Shanghai Institutes for Biologic Sciences, Chinese Academy of Sciences. L-02, QGY7701, HepG2, SMMC-7721, BEL-7402, SK-HEP-1 and Li-7 cells were maintained in RPMI 1640 containing 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) in a humidified incubator with 5% CO<sub>2</sub> at 37 °C and SK-HEP-1 cells were maintained in Eagle's Minimum Essential Medium (EMEM) (Invitrogen) supplemented with 10% FBS under the same environment. 293 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen) plus 10% FBS.

#### *3.2. Plasmid Construction*

Human genomic DNA was extracted from L-02 cells and used for amplification of the template of the precursor sequence of miR-590-5P. The primers used were: 5'-GGAATTCTTCAGTTGTAA CCCAG-3' and 5'-CGGGATCCTTGAGATGTCACCAA-3'. The PCR product was digested using EcoR I and BamH I and ligated into linear pCDH-EF1-GFP vector (System Biosciences) and transformed into DH5 $\alpha$  competent cells. The obtained vector was called pmiR-590-5P vector. 3'-untranslated region (3'-UTR) of human S100A10 was amplified from cDNA obtained through the reverse transcription of total RNA of L-02 cells. The following primers were used: wild type: 5'-GCTCTAGAAATGAGCAGTTCGCTCCTCC-3' and 5'-GCTCTAGAACAATACAAAATC AAAAGCTTATC-3'; mutated type: 5'-GCTCTAGAAATGAGCAGTTCGCTCCTCC-3' and

5'-GCTCTAGAAACAATACAAAAATCAAATATGATCCTGGTA-3'. The products were digested with Xba I and inserted into pGL3-promotor vector (Promega, Madison, WI, USA). The resulting vectors were called as pGL-WT and pGL-MT, respectively. All the sequences of constructed vectors were verified by PCR-agarose electrophoresis and sequence analysis.

### *3.3. Cell Transfection and Luciferase Assay*

Using Lipofectamine 2000 according to the manufacturer's instructions 293 cells were transfected with the pmiR-590-5P, pGL-WT and pGL-MT. Forty eight hours after transient transfection, the cells were harvested and luciferase assays were performed. The relative luciferase activities (ratios of firefly and renilla luciferase activity) of lysates were measured by the dual luciferase reporter assay system (Promega, Madison, WI, USA).

### *3.4. Lentivirus Package and Cell Infection*

In DMEM supplemented with 10% FBS 293TN Producer Cell Line (SBI) were cultured. One day before transfection, cells were seeded at  $5 \times 10^5$  per 10 cm dish. Lenti-miR-590-5P vector and pPACK Packaging Plasmid Mix (SBI, Mountain View, CA, USA) were co-transfected using Lipofectamine 2000 (Invitrogen). After 24 h, the medium was replaced with DMEM plus 2% FBS. After 48 h, the supernatant was harvested, cleared by centrifugation at 5000 rpm at room temperature for 5 min, and passed through a 0.45  $\mu$ m PVDF membrane. The viral titer was measured by gradient dilution according to the expression level of GFP following the manufacturer's instructions. The packaged lentiviruses were named Lv-miR-590-5P and Lv-Control.

One day after seeding, HepG2 cells were infected with Lv-miR-590-5P or Lv-Control diluted by DMEM at a multiplicity of infection (MOI) of 10 and the medium was refreshed after 24 h; the infection efficiency was assessed by fluorescence microscopy 96 h after infection. The expression of miR-590-5P in the infected HepG2 cells was detected by quantitative PCR. Then, the cells were subject to western blot analysis of S100A10, cell proliferation assay and other assays.

### *3.5. Real Time PCR*

Total RNA was isolated from cells at the exponential phase or from HepG2 cells at 96 h after the infection of Lv-control or Lv-miR-590-5P using Trizol Reagent (Invitrogen) and was reversely transcribed into cDNA using M-MLV Reverse Transcriptase (Takara BIO, Dalian, China) with specific primers for U6 snRNA and has-miR-590-5p: 5'-TACCTTGCGAAGTGCTTAAAC-3' and 5'-GTCGTATCCAGTGC GTGTCGTGGAGTCGGCAATTGCACTGGATACGACCTGCA-3', respectively. Real-time PCR was performed using SYBR<sup>®</sup> Premix Ex Taq<sup>™</sup> kit (Takara, Dalian, China) and TP800 System (Takara). The following primers were used for quantification of human U6 snRNA and has-miR-590-5p: U6 snRNA: 5'-GTGCTCGCTTCGGCAGCACAT-3' and 5'-TACCTTGCGAAGTGCTTAAAC-3'; and has-miR-590-5p: 5'-GAGCTTATTCATAAAAGT-3' and 5'-TCCACGACACGCACTGGATACGAC-3'; 2  $\mu$ L cDNA from the reverse transcription reaction was used as the template for real-time PCR. Cycling parameters were as follows: 40 cycles of denaturation at 95 °C for 10 s, annealing at 55 °C (U6) or 60 °C (miR-590-5p) for 20 s and extension

at 72 °C for 20 s. The has-miR-590-5p levels were normalized to U6 using the delta-delta Ct method. Each RNA sample was run in triplicate.

### *3.6. Western Blotting*

Western blotting was performed to detect the expression of S100A10 in several HCC cell lines and a normal liver cell line, as well as HepG2 cells infected with Lv-miR-590-5P or Lv-Control. After being cultured for 48 h, or 96 h after infection, the cells were harvested and total protein was isolated with M-PER® Mammalian protein extraction reagent (Pierce, Rockford, IL, USA) according to the manufacturer's protocol. The protein concentrations were assessed using the BCA protein assay. Samples with the same amount of total protein were separated by SDS-PAGE using 14% (for S100A10) or 13% (for beta-actin) gel and transferred onto PVDF membranes (Millipore, Boston, MA, USA). The membranes were blocked with TBST containing 5% non-fat milk and incubated with antibodies against human S100A10 (1:200) (Santacruz) and beta-actin (1:1000) (Cell Signaling Technology) at 4 °C overnight. After washing, the membranes were then incubated with a HRP-conjugated anti-rabbit IgG antibody (Cell Signaling Technology, Boston, MA, USA) and detected by enhanced chemiluminescence reagents (Pierce). Beta-actin was used as an endogenous reference.

The change of expression of proteins involved into the WNT pathway and phosphorylation level of  $\beta$ -catenin in HepG2 cells infected by Lv-miR-590-5P were also assessed by western blotting. The Lv-miR-590-5P or Lv-control infected cells were harvested for protein extraction 96 h after infection. The antibodies against Wnt5a (1:1000) (Abcam, Cambridge, MA, USA), phospho- $\beta$ -catenin (1:1000) (Abcam), cMyc (1:800) (Abcam), cyclin D1 (1:800) (Abcam) and beta-actin (1:800) (Cell Signaling Technology, Boston, MA, USA) were used to detect the corresponding proteins according to the instructions.

### *3.7. Cell Proliferation Assays*

The control and miR-590-5P over-expression HepG2 cells were reseeded into 96-well plates at  $1 \times 10^4$  cells per well. Then 10  $\mu$ L CCK-8 solution (Dojindo, Kumamoto-ken, Japan) was added into each well at 24, 48 or 72 h after seeding. After incubation for an additional 4 h, the supernatants were transferred to new 96-well plates and the absorbance of each well at 450 nm was determined.

Cell cycle analysis. HepG2 cells were infected with Lv-miR-590-5P or Lv-Control as described above. The cells at the logarithmic growth phase were trypsinized, washed with phosphate buffered saline (PBS) twice, and then fixed with 70% ethanol at 4 °C overnight. The fixed cells were washed with PBS twice, resuspended in 100  $\mu$ L PBS (containing 100  $\mu$ g/mL ribonuclease A and 50  $\mu$ g/mL propidium iodide), and incubated at room temperature for 30 min. The cell cycle distribution was detected by a BD FACSCalibur flow cytometer.

### *3.8. Statistical Analysis*

All values are presented as mean  $\pm$  standard deviation (SD). Statistical significance was evaluated using the Student's *t*-test for unpaired comparison; *p* values  $\leq 0.05$  were taken as the level of significance.

#### **4. Conclusions**

In summary, this is the first work to show that S100A10 protein production and cellular proliferation are effectively inhibited *in vitro* by lentivirus-mediated over-expression of miR-590-5P in HepG2 cells. To give more relevant information and suggestions for the development of therapies for human lung malignancies, more thorough *in vitro* and *in vivo* investigations should be conducted.

#### **References**

1. Chen, J.G.; Zhang, S.W. China's liver cancer epidemic: History, Current Situation, and Prospects. *Cancer Biol. Semin.* 2011, 21, 59–69.
2. Santamaria-Kisiel, L.; Shaw, G.S. Using chimaeric S100A11-S100A10 proteins, the areas important for the open conformation of S100A10 were identified. *J. Biochem.* 2011, 434, 37–48.
3. Glenney, J.R., Jr.; Tack, B.F. Characterization of the tyrosine phosphorylation site and homology with S-100 in the amino-terminal sequence of p36 and related p10. *Proceedings of the National Academy of Science, USA*, 1985, 82, 7884–7888.
4. Weber, K.; Gerke, V. Identification of p36K phosphorylated following transformation by the Rous sarcoma virus using a protein isolated from brush boundaries; binding to non-erythroid spectrin and F-actin in a calcium-dependent manner. 1984, 3, 227-233, *EMBO J.*
5. Annexin II tetramer: Structure and function, Waisman, D.M. *Mol. Cell. Biochem.* 1995, 301–322, 149–150.
6. Gerke, V.; Moss, S.E. Membrane dynamics and annexins. 129–154 in *Biochim. Biophys. Acta* 1997, 1357.
7. Weber, K.; Gerke, V. The S-100 protein of glial cells has a sequence with the regulatory chain in the p36-kd substrate complex of viral tyrosine-specific protein kinases. 1985, 4, 2917–2920; *EMBO J.*
8. Changes in 5-HT<sub>1B</sub> receptor function by p11 in depression-like conditions (Svenningsson, P.; Chergui, K.; Racheff, I.; Flajolet, M.; Zhang, X.; El Yacoubi, M.; Vaugeois, J.M.; Nomikos, G.G.; Greengard, P.). *Science* 311, 77–80, 2006.
9. Parker-Schmidt, J.L.; Flajolet, M.; Maller, A.; Chen, E.Y.; Qi, H.; Svenningsson, P.; Greengard, P. p11's function in the behavioral and cellular impacts of 5-HT<sub>4</sub> receptor activation. *J. Neurosci.* 2009, 29, 1937–1946.
10. Girard, C.; Tinel, N.; Terrenoire, C.; Romey, G.; Lazdunski, M.; Borsotto, M. p11, an auxiliary protein linked to the background K<sup>+</sup> channel, TASK-1, is an annexin II subunit. 2002, 21, 4439–4448, *EMBO J.*
11. Rengunta, V.; Yuan, H.; Zuzarte, M.; Rinne, S.; Koch, A.; Wischmeyer, E.; Gao, Y.; Karschin, A.; Jacob, R.; Schwappach, B.; et al. The potassium channel receives an endoplasmic reticulum-localization signal from the retention factor p11. *Task 1.* 168–181 in *Traffic* 2006, 7.
12. Van de Graaf, S.F.J.; Hoenderop, J.G.J.; Gkika, D.; Lamers, D.; Prenen, J.; Rescher, U.; Gerke, V.; Staub, O.; Nilius, B.; Bindels, R.J. Association of the S100A10 annexin 2 complex is necessary for the functional expression of the epithelial Ca<sup>2+</sup> channels (TRPV5 and TRPV6). 2002, 22, 1478–1487; *EMBO J.*
13. Waisman, D.M.; Filipenko, N.R.; Kwon, M.; MacLeod, T.J. The interaction of the phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits with tissue plasminogen activator, plasminogen, and plasmin is described. 2003, 278, 25577–25584; *J. Biol. Chem.*
14. O'Connell, P.A.; Waisman, D.M.; Hipps, K.D.; Surette, A.P. Tumor-promoting macrophage migration into tumor locations depends on the plasminogen receptor S100A10. *Cancer Res.* 71, 6676–6683, 2011.
15. Bartel, D.P. MicroRNAs: Biogenesis, mechanism, function, and genomics. *Cell* 2004, 116, 281-297.
16. He, L.; Hannon, G.J. MicroRNAs: Tiny RNAs that play a significant part in the regulation of genes. 5, 522–531, *Nat. Rev. Genet.* 2004.

## Frontiers in Clinical Trials and Drug Interactions

### Volume1, Issue2, 2025

17. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Thousands of human genes are microRNA targets, according to conserved seed pairing, which is often accompanied by adenosines. 15–20 in *Cell* 2005, 120.
18. Farh, K.K.; Grimson, A.; Jan, C.; Lewis, B.P.; Johnston, W.K.; Lim, L.P.; Burge, C.B.; Bartel, D.P. The extensive influence of mammalian microRNAs on mRNA evolution and suppression. 1817–1821 in *Science* 2005, 310.
19. Pauli, A.; Schier, A.F.; Rinn, J.L. Non-coding RNAs as embryogenesis regulators. 2011; *Nat. Rev. Genet.* 12, 136–149.
20. Leaman, D.; Chen, P.Y.; Fak, J.; Yalcin, A.; Pearce, M.; Unnerstall, U.; Marks, D.S.; Sander, C.; Tuschl, T.; Gaul, U. The crucial and distinct roles of microRNAs in *Drosophila* development are revealed via antisense-mediated depletion. *Cell* 2005, 121, 1097–1108.